Versant Venture Management, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.

Quarter-by-quarter ownership
Versant Venture Management, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$22,629,548
-19.1%
498,5580.0%12.03%
-63.8%
Q2 2023$27,989,046
+24.1%
498,5580.0%33.20%
-29.4%
Q1 2023$22,549,778
+11.3%
498,5580.0%47.01%
+12.1%
Q4 2022$20,266,383
-37.8%
498,5580.0%41.94%
-24.5%
Q3 2022$32,581,000
+7.5%
498,5580.0%55.55%
+19.6%
Q2 2022$30,297,000
-3.2%
498,5580.0%46.45%
+48.7%
Q1 2022$31,294,000
-17.2%
498,5580.0%31.24%
+54.6%
Q4 2021$37,781,000
-32.3%
498,5580.0%20.21%
-12.6%
Q3 2021$55,804,000
-32.2%
498,558
-2.0%
23.11%
-15.3%
Q2 2021$82,330,000
-56.5%
508,558
-67.3%
27.28%
-26.1%
Q1 2021$189,472,000
-59.3%
1,554,960
-48.9%
36.92%
-23.6%
Q4 2020$465,525,000
+53.3%
3,040,462
-16.3%
48.34%
-13.0%
Q3 2020$303,752,000
-99.9%
3,631,656
-13.2%
55.60%
+25.9%
Q2 2020$307,413,373,000
+73.5%
4,183,064
-0.5%
44.16%
-9.1%
Q1 2020$177,224,616,000
-30.8%
4,205,6150.0%48.60%
-37.0%
Q4 2019$256,142,982,000
+47.6%
4,205,615
-0.7%
77.19%
+15.0%
Q3 2019$173,546,331,000
-13.3%
4,233,870
-0.4%
67.15%
+15.2%
Q2 2019$200,122,625,000
+31.9%
4,248,8880.0%58.31%
+16.6%
Q1 2019$151,770,279,000
+47.2%
4,248,888
+17.7%
50.00%
-2.0%
Q4 2018$103,105,530,000
-35.6%
3,608,8740.0%51.04%
-6.2%
Q3 2018$160,053,562,000
-24.5%
3,608,8740.0%54.44%
-17.7%
Q2 2018$212,057,436,000
+0.7%
3,608,874
-21.7%
66.16%
-1.8%
Q1 2018$210,551,322,0004,606,24267.34%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q2 2022
NameSharesValueWeighting ↓
Versant Venture Management, LLC 508,558$82,330,00027.28%
Valiant Capital Management, L.P. 307,700$49,814,0003.74%
NEA Management Company, LLC 1,590,002$257,405,0003.35%
NIA IMPACT ADVISORS, LLC 39,891$6,458,0003.15%
Ikarian Capital, LLC 200,000$32,379,0002.62%
Soleus Capital Management, L.P. 103,114$16,693,0002.57%
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 157,334$25,471,0002.47%
Capital Impact Advisors, LLC 45,440$7,356,0002.37%
ARK Investment Management 7,776,119$1,258,876,0002.34%
Sassicaia Capital Advisers LLC 13,513$2,188,0002.28%
View complete list of CRISPR THERAPEUTICS AG shareholders